AGYTF.US Allergy Therapeutics plc

Healthcare Pharmaceuticals USA Stocks
0.1500 USD
Close of Nov 12, 2026
0.1100 0.1500
Market cap
USD 950M
P/E
-
P/B
169.01x
ROE
-1,874.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Dec 2025.

Is AGYTF.US undervalued?

Graham number

The Graham number of Allergy Therapeutics plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Allergy Therapeutics plc fundamental analysis

No fundamental analysis for Allergy Therapeutics plc yet.

Allergy Therapeutics plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Allergy Therapeutics plc

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venom…

Full company profile